Deucravacitinib治疗中重度斑块状银屑病:两项3期试验52周汇总安全性与耐受性
基于POETYK PSO-1和PSO-2两项3期试验的汇总分析,共纳入1683例中重度斑块状银屑病患者,随机接受安慰剂、deucravacitinib或阿普米司特治疗。52周数据显示deucravacitinib总体耐受良好,各治疗组不良事件发生率相似,严重不良事件低且组间均衡,deucravacitinib停药率低于安慰剂或阿普米司特,未出现新的安全信号。
要点
- deucravacitinib治疗52周总体耐受良好,停药率低于安慰剂或阿普米司特。
- 严重感染暴露调整发生率:安慰剂0.8/100PY,deucravacitinib 1.7/100PY,阿普米司特1.8/100PY。
- deucravacitinib组痤疮和毛囊炎发生率高于安慰剂,但未出现新的安全信号。
核心结论
- deucravacitinib在中重度斑块状银屑病患者中治疗52周耐受良好,安全性可接受,未出现新的安全信号。
研究设计与样本
- 汇总POETYK PSO-1和PSO-2两项3期试验的安全性数据,共纳入1683例中重度斑块状银屑病患者。
- 患者按1:2:1随机接受口服安慰剂、deucravacitinib或阿普米司特治疗。
主要发现
- 各治疗组不良事件发生率相似,严重不良事件发生率低且组间均衡。
- deucravacitinib停药率低于安慰剂或阿普米司特。
- deucravacitinib组实验室参数均值较基线无临床意义变化,也无向CTCAE≥3级异常转移的报道。
关键数值与推荐
- 严重感染暴露调整发生率:安慰剂0.8/100PY,deucravacitinib 1.7/100PY,阿普米司特1.8/100PY。
- 主要不良心血管事件:安慰剂1.2/100PY,deucravacitinib 0.3/100PY,阿普米司特0.9/100PY。
- 静脉血栓栓塞事件:安慰剂0,deucravacitinib 0.2/100PY,阿普米司特0。
- 恶性肿瘤:安慰剂0,deucravacitinib 1.0/100PY,阿普米司特0.9/100PY。
- 带状疱疹:安慰剂0.4/100PY,deucravacitinib 0.8/100PY,阿普米司特0。
临床怎么用
- deucravacitinib可作为中重度斑块状银屑病长期治疗选择,需关注痤疮、毛囊炎及带状疱疹等不良事件。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Two phase 3 trials, POETYK PSO-1 and PSO-2, previously established the efficacy and overall safety of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in plaque psoriasis. OBJECTIVES: To further assess the safety of deucravacitinib over 52 weeks in the pooled population from these two trials. METHODS: Pooled safety data were evaluated from PSO-1 and PSO-2 in which patients with moderate-to-severe plaque psoriasis were randomized 1:2:1 to receive oral placebo, deucravacitinib or apremilast. RESULTS: A total of 1683 patients were included in the pooled analysis. Adverse event (AE) incidence rates were similar in each treatment group, serious AEs were low and balanced across groups, and discontinuation rates were lower with deucravacitinib versus placebo or apremilast. No new safety signals emerged with longer deucravacitinib treatment. Exposure-adjusted incidence rates of AEs of interest with placebo, deucravacitinib and apremilast, respectively, were as follows: serious infections (0.8/100 person-years [PY], 1.7/100 PY, and 1.8/100 PY), major adverse cardiovascular events (1.2/100 PY, 0.3/100 PY, and 0.9/100 PY), venous thromboembolic events (0, 0.2/100 PY, and 0), malignancies (0, 1.0/100 PY and 0.9/100 PY), herpes zoster (0.4/100 PY, 0.8/100 PY, and 0), acne (0.4/100 PY, 2.9/100 PY, and 0) and folliculitis (0, 2.8/100 PY, and 0.9/100 PY). No clinically meaningful changes from baseline in mean levels, or shifts from baseline to CTCAE grade ≥3 abnormalities, were reported in laboratory parameters with deucravacitinib. CONCLUSIONS: Deucravacitinib was well-tolerated with acceptable safety over 52 weeks in patients with psoriasis.
引用
- Strober B, Blauvelt A, Warren RB, et al. Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2). J Eur Acad Dermatol Venereol. 2024. PMID: 38451052. doi:10.1111/jdv.19925
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。